Legal and Recreational Sales of Cannabis Products Expected to Grow

Tuesday, December 19, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+ News Commentary

NEW YORK, December 19, 2017 /PRNewswire/ --

According to data provided

by New Frontier Data, in partnership with Arcview Market Research, the legalization of cannabis in California, Massachusetts, Nevada, Florida,
Arkansas and North Dakota will result in new markets that account for $7.1 billion in sales by 2020. The research estimates that the overall U.S. cannabis market will exceed $20.9 billion by 2020. Nevada presents significant opportunities for investors and businesses in the legal cannabis market. New Frontier Data explains that Nevada ranks as a top tourism destination, due to generous patient reciprocity laws, and the allowance for medical cannabis businesses to be formed as for-profit enterprises are all important factors expected to boost the industry. The combined medical and adult use sales in Nevada are expected to reach about $622 million by 2020. Body and Mind Inc. (OTC: BMMJ), Lexaria Bioscience Corp. (OTC: LXRP), Vitality Biopharma, Inc. (OTC: VBIO), Kush Bottles, Inc. (OTC: KSHB), United Cannabis Corporation (OTC: CNAB)

New Frontier Data Founder & CEO Giadha DeCarcer, said, "The passage of Nevada's adult use legalization measure opens the floodgates for America's adult playground. As the most sophisticated hospitality destination in the country drawing an estimated 55 million visitors in 2016 alone, the integration of cannabis into Nevada's economy will create an opportunity for canna-tourism on a scale not seen before in the country."

Body and Mind Inc. (OTC: BMMJ) also listed on the Canadian Stock Exchange under the Ticker 'BAMM'. Yesterday the company announced breaking news that, "two significant transactions. The Company has reached an agreement with a real estate investment group, led by the Company's President, who will purchase a building adjacent to the existing facility and lease it back to a newly formed partnership called Pepper Lane North LLC ("PLN" or "Partnership") on a long-term basis with renewal options. PLN is a strategic partnership between BAMM and one of the preeminent dispensary chains in the State of Nevada. BAMM's partner will also transfer an active cultivation license to the facility and all expenditures under PLN will be funded on a 50/50 basis. The new facility will primarily consist of flowering rooms as production, packaging, distribution, and head office functions will remain at the existing facility. BAMM has also earmarked approximately 4,000 square feet of frontage for a dispensary upon receipt of a retail license. It is contemplated that at least half of the sales under PLN will be sold to BAMM's partner through their existing dispensary network. In addition, BAMM has signed an operating and management agreement with PLN and will receive the greater of USD$15,000/month or 10% of PLN's net profits.

The Company's CEO Leonard Clough commented, "On a combined basis, BAMM will have approximately 50,000 sq. feet of facilities under management, an increase of approximately 150%, but what is more significant is that we anticipate an increase in production of over 300% providing BAMM with a significant near term growth profile. We anticipate a decline in per unit costs going forward, greater efficiencies in our distribution and packaging departments, and meaningful economies of scale. Our funding agreement under PLN also provides the added bonus of leverage - significant growth for a relatively low capex investment. Our pursuit of 100,000 sq. feet is well underway."

Under the Partnership, each party has provided an initial capital contribution to PLN in the amount of USD $250,000. These funds will first be applied as a non-refundable deposit towards securing the building lease of approximately 30,000 square feet located in close proximity to the Company's current operations in Las Vegas, Nevada. The new facility will require renovations and build-out costs of approximately USD$3,700,000. The renovation and build-out costs will be funded by PLN on an equity interest basis and BAMM expects the new facility to be operational in the latter part of 2018."

Lexaria Bioscience Corp. (OTCQB: LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Recently, the company announced the United States Patent and Trademark Office ("USPTO") has granted patent number 9,839,612 B2 for the use of DehydraTECHTM technology as a delivery platform for a wide variety of Active Pharmaceutical Ingredients ("APIs") including all cannabinoids including THC; fat soluble vitamins; non-steroidal anti-inflammatory pain medications ("NSAIDs"); and nicotine. "Lexaria has now locked-up the IP for its next-generation drug delivery system" said Chief Executive Officer Chris Bunka. "This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world's first nicotine edibles for the smokeless tobacco industry, or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market. Vitality Biopharma, Inc. (OTCQB: VBIO) is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. On November 1, 2017, the company announced completion of pivotal manufacturing agreements that enable the production of clinical-grade cannabinoid pharmaceuticals at its R&D facilities in California. In early 2017, after receiving approval from the U.S. DEA for its cannabinoid pharmaceutical research, Vitality contracted with a research services provider to obtain new software and protocols to support its internal manufacturing team and to ensure GMP manufacturing compliance.  The Company has implemented these protocols for initial production of cannabosides, the company's cannabinoid prodrugs that are designed to target the gastrointestinal tract and thereby avoid the intoxicating side effects of THC.  Vitality has also recently entered into a services agreement with a specialist analytical chemistry firm, in order to provide independent verification of the Company's analytical procedures and batch release testing, in compliance with FDA and international regulatory standards. Kush Bottles, Inc. (OTCQB: KSHB) is a dynamic sales platform that provides unique products and services for both businesses and consumers in the cannabis industry. On November 28, 2017, the company reported financial results for its fiscal year ended August 31, 2017. Revenue was up 129% Year-over-Year to $18.8 million; revenues included four months of sales from CMP Wellness which was acquired on May 1, 2017. Net income, including $943,000 in non-cash stock compensation, $301,000 in depreciation and amortization expense and $4.6 million in SG&A, was $69,000 compared to net income of $72,000 in fiscal year 2016; the increase in operating expenses stems from costs associated with the acquisition of CMP Wellness, as well as higher SG&A costs to support an expanded outside sales program. United Cannabis Corporation (OTCQB: CNAB) is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. Recently, the company announced that Jamaica's Ministry of Health has approved its patent-protected Prana Medicinal Sublinguals and Prana Medicinal Transdermals for use by registered medicinal cannabis patients. The Prana Collection is the foundation of the Company's cannabis-centric formulations, which patients have found effective in providing relief from the symptoms of arthritis, neuropathy, acute pain, joint aches, muscle tension, muscle spasms, muscle recovery, migraines, and various skin conditions.

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, expects to be compensated five thousand dollars for financial news dissemination and PR services by body and mind inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

Media Contact: +1-877-601-1879 Url:


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store